Mitochondrial Disease Therapies Market 2019, with Forecasts to 2030 -

DUBLIN--()--The "Mitochondrial Disease Therapies Market, 2019-2030" report has been added to's offering.

Mitochondrial diseases are characterized by chronic, genetic and progressive medical symptoms that arise due to inherited or spontaneous mutations in mitochondrial DNA, or in some cases, nuclear DNA, which adversely alter the function of mitochondria. Such clinical conditions are rare and are known to affect multiple parts of the body, including neurons and nerves, kidneys, heart, liver, eyes, ears, and pancreas. It is worth highlighting that over 300 mutations have been identified and are associated with various mitochondrial diseases. Examples of diseases that are caused due to mutations in mitochondrial DNA include Leber's hereditary optic neuropathy (LHON), Leigh syndrome, mitochondrial DNA depletion syndrome, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), and myoclonic epilepsy with ragged red fibers (MERRF).

In the US, mitochondrial diseases are known to annually affect 1 in 5,000 individuals. It is also estimated that 1,000-4,000 children are born with a mitochondrial disease every year, in the same region. Primary mitochondrial diseases are usually difficult to diagnose. In many cases, clinicians and medical professionals are compelled to use the term possible mitochondrial disease, indicating that based on the presenting symptoms they suspect a patient to be suffering from a mitochondrial disease. However, they are unable to confirm the condition via genetic diagnosis. Such instances are further complicated by the aforementioned uncertainty, leading to delays in treatment and subsequent deterioration in the patient's quality of life. Currently, several industry stakeholders are engaged in efforts to develop disease-modifying interventions for treating different mitochondrial diseases, in addition to drug/therapy candidates that offer symptomatic relief. There are several non-profit organizations that have been established across the globe to support individuals suspected/diagnosed with mitochondrial diseases and also fund research / clinical studies being conducted for the treatment of such conditions. In the coming years, the market is anticipated to grow at a significant pace as more novel therapy solutions are approved by regulatory authorities and enter the market.

The Mitochondrial Disease Therapies Market, 2019-2030 report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of therapeutics designed to treat mitochondrial diseases. It features an in-depth analysis, highlighting the capabilities of stakeholder companies/organizations engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development of lead candidates, type of molecule, type of therapy, path to clinic, target disease indication, and route of administration of the drugs / therapies that are being developed for the treatment of different mitochondrial diseases.
  • Detailed profiles of the players that are engaged in the development of therapies for mitochondrial diseases, featuring an overview of the company, its financial information, a description of its product portfolio, recent collaborations and an informed future outlook.
  • An analysis of close to 200 peer-reviewed, scientific articles published during the period 2014-2019, highlighting the research focus within this niche industry segment.
  • A list of key opinion leaders (KOLs) within this domain, featuring detailed 2X2 matrices to assess the relative experience of key individuals, who were shortlisted based on their contributions to this field.
  • A study of the various grants that have been awarded to research institutes engaged in projects related to different types of mitochondrial diseases, between 2015 and 2019, highlighting various important parameters, such as year of award, support period, amount awarded, funding institute, grant type, responsible study section, focus area and type of recipient organization.

Companies Mentioned

  • AADI Bioscience
  • Alkeus Pharmaceuticals
  • Allergan
  • Anavex Life Sciences
  • Animas
  • Astellas Pharma
  • Biovista
  • Cerecor
  • Illumina
  • Innocoll
  • Institut de la Vision
  • Insulet
  • Intercept Pharmaceuticals
  • MD Stem Cells
  • Medosome Biotec
  • Medtronic
  • Merrimack College
  • Metro International Biotech
  • Minoryx Therapeutics
  • Minovia Therapeutics
  • Mission Therapeutics
  • MitoAction
  • Mitobridge
  • MitoCanada Foundation
  • Mitochon Pharmaceuticals
  • MitoEAGLE
  • Mitotech
  • NeuroVive Pharmaceutical
  • Novartis
  • Oroboros Instruments
  • Perlara
  • Pharmathen
  • Reata Pharmaceuticals
  • Relmada Therapeutics
  • Reneo Pharmaceuticals
  • Retrotope
  • SOM Biotech
  • Spark Therapeutics
  • Stealth BioTherapeutics
  • Sumitomo Dainippon Pharma
  • Taisho Toyama Pharmaceuticals
  • Takeda Pharmaceutical
  • Tandem Diabetes Care
  • uniQure
  • YUNGJIN Pharmaceutical

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900